<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616629</url>
  </required_header>
  <id_info>
    <org_study_id>D3190C00005</org_study_id>
    <secondary_id>2007-0003455-36 (EudraCT No)</secondary_id>
    <nct_id>NCT00616629</nct_id>
  </id_info>
  <brief_title>Cardiac Electrophysiological Study</brief_title>
  <official_title>A Multi-centre, Double-blind, Randomised, Placebo-controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological
      properties and intracardiac pressures
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation))</measure>
    <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product</time_frame>
    <description>Absolute change, after - before infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RAERP (Right Atrial Effective Refractory Period)</measure>
    <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product</time_frame>
    <description>Absolute change, after - before infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VERP (Ventricular Effective Refractory Period)) and Other Electrophysiological and Electrocardiographic Variables; RR, P Wave Duration, PR, QRS, QTend, QTcF, QTtop, QTend - QTtop)</measure>
    <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product</time_frame>
    <description>Absolute change, after - before infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF (Interval From the Beginning of the Q or R Wave to the End of the T Wave in the Surface ECG, Corrected for Changes in RR Interval Using Fridericia' Formula =QT/RR1/3 Interval in Seconds)</measure>
    <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product. ECG measurements, including QTcF, are available from several additiona</time_frame>
    <description>Absolute change, after - before infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Observed for AZD1305</measure>
    <time_frame>During and after infusion</time_frame>
    <description>A total of 13 scheduled PK samples for each patient during and after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Total of AZD1305 (Umol*h/L)</measure>
    <time_frame>Based on PK samples during and after infusion</time_frame>
    <description>A total of 13 scheduled PK samples for each patient during and after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Had at Least One AE</measure>
    <time_frame>During active treatment period</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Atrial Flutter</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1305</intervention_name>
    <description>Intravenous infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with atrial flutter (with a ventricular rate of &lt;100 beats/minute at
             enrolment), scheduled for curative catheter ablation

          -  Sinus rhythm at randomisation

        Exclusion Criteria:

          -  QTc (Fridericia, QTcF ) &gt;450 ms measured in sinus rhythm at randomisation,

          -  Serum potassium below 3.8 or above 5.0 mmol/L or plasma potassium below 3.6 or above
             5.0 mmol/L

          -  QRS duration &gt;120 ms at randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Toivonen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gŏteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkŏping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ŏrebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <results_first_submitted>January 24, 2011</results_first_submitted>
  <results_first_submitted_qc>August 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2011</results_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>AstraZeneca AZD1305 Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 68 patients were enrolled into the study. The study randomised 55 patients and 50 of those patients received study drug. All patients who received study drug completed the study.</recruitment_details>
      <pre_assignment_details>At the pre-entry visit, which took place within 14 days before the planned catheter ablation (Study Day), patients underwent a full clinical assessment including a physical examination, ECG recording, Bood pressure(BP)/heart rate measurement, routine laboratory tests, and transthoracic echocardiography (TTE, if not done within the prior 6 months).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1305 Dose Group 1</title>
          <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
        </group>
        <group group_id="P2">
          <title>AZD1305 Dose Group 2</title>
          <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
        </group>
        <group group_id="P3">
          <title>AZD1305 Dose Group 3</title>
          <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
        </group>
        <group group_id="P4">
          <title>AZD1305 Dose Group 4</title>
          <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Corresponding placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">Two patients never received study drug</participants>
                <participants group_id="P2" count="14">Two patients never received study drug</participants>
                <participants group_id="P3" count="14">One patient never received study drug</participants>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AV-block</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD1305 Dose Group 1</title>
          <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
        </group>
        <group group_id="B2">
          <title>AZD1305 Dose Group 2</title>
          <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
        </group>
        <group group_id="B3">
          <title>AZD1305 Dose Group 3</title>
          <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
        </group>
        <group group_id="B4">
          <title>AZD1305 Dose Group 4</title>
          <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Corresponding placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="14"/>
                    <measurement group_id="B2" value="62" spread="6"/>
                    <measurement group_id="B3" value="60" spread="8"/>
                    <measurement group_id="B4" value="50" spread="23"/>
                    <measurement group_id="B5" value="62" spread="6"/>
                    <measurement group_id="B6" value="56" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation))</title>
        <description>Absolute change, after - before infusion</description>
        <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation))</title>
          <description>Absolute change, after - before infusion</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="-15" lower_limit="-15" upper_limit="40"/>
                    <measurement group_id="O2" value="43" spread="0" lower_limit="0" upper_limit="210"/>
                    <measurement group_id="O3" value="55" spread="-5" lower_limit="-5" upper_limit="85"/>
                    <measurement group_id="O4" value="50" spread="40" lower_limit="40" upper_limit="60"/>
                    <measurement group_id="O5" value="-10" spread="-90" lower_limit="-90" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RAERP (Right Atrial Effective Refractory Period)</title>
        <description>Absolute change, after - before infusion</description>
        <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>RAERP (Right Atrial Effective Refractory Period)</title>
          <description>Absolute change, after - before infusion</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="-5" lower_limit="-5" upper_limit="40"/>
                    <measurement group_id="O2" value="42" spread="0" lower_limit="0" upper_limit="75"/>
                    <measurement group_id="O3" value="84" spread="-30" lower_limit="-30" upper_limit="165"/>
                    <measurement group_id="O4" value="135" spread="100" lower_limit="100" upper_limit="170"/>
                    <measurement group_id="O5" value="-12" spread="-90" lower_limit="-90" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VERP (Ventricular Effective Refractory Period)) and Other Electrophysiological and Electrocardiographic Variables; RR, P Wave Duration, PR, QRS, QTend, QTcF, QTtop, QTend - QTtop)</title>
        <description>Absolute change, after - before infusion</description>
        <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>VERP (Ventricular Effective Refractory Period)) and Other Electrophysiological and Electrocardiographic Variables; RR, P Wave Duration, PR, QRS, QTend, QTcF, QTtop, QTend - QTtop)</title>
          <description>Absolute change, after - before infusion</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="-25" lower_limit="-25" upper_limit="30"/>
                    <measurement group_id="O2" value="41" spread="5" lower_limit="5" upper_limit="145"/>
                    <measurement group_id="O3" value="59" spread="25" lower_limit="25" upper_limit="110"/>
                    <measurement group_id="O4" value="65" spread="45" lower_limit="45" upper_limit="85"/>
                    <measurement group_id="O5" value="3" spread="-25" lower_limit="-25" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF (Interval From the Beginning of the Q or R Wave to the End of the T Wave in the Surface ECG, Corrected for Changes in RR Interval Using Fridericia’ Formula =QT/RR1/3 Interval in Seconds)</title>
        <description>Absolute change, after - before infusion</description>
        <time_frame>Measurements were obtained twice, from the invasive electrophysiological measurements made before and 20 min (or more) after the start of administration of the investigational product. ECG measurements, including QTcF, are available from several additiona</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF (Interval From the Beginning of the Q or R Wave to the End of the T Wave in the Surface ECG, Corrected for Changes in RR Interval Using Fridericia’ Formula =QT/RR1/3 Interval in Seconds)</title>
          <description>Absolute change, after - before infusion</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="-2" lower_limit="-2" upper_limit="42"/>
                    <measurement group_id="O2" value="65" spread="13" lower_limit="13" upper_limit="150"/>
                    <measurement group_id="O3" value="79" spread="31" lower_limit="31" upper_limit="128"/>
                    <measurement group_id="O4" value="65" spread="59" lower_limit="59" upper_limit="70"/>
                    <measurement group_id="O5" value="4" spread="-51" lower_limit="-51" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax Observed for AZD1305</title>
        <description>A total of 13 scheduled PK samples for each patient during and after infusion</description>
        <time_frame>During and after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax Observed for AZD1305</title>
          <description>A total of 13 scheduled PK samples for each patient during and after infusion</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178" spread="0.104" lower_limit="0.104" upper_limit="0.279"/>
                    <measurement group_id="O2" value="0.692" spread="0.368" lower_limit="0.368" upper_limit="1.82"/>
                    <measurement group_id="O3" value="1.46" spread="0.931" lower_limit="0.931" upper_limit="2.81"/>
                    <measurement group_id="O4" value="2.41" spread="2.24" lower_limit="2.24" upper_limit="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Total of AZD1305 (Umol*h/L)</title>
        <description>A total of 13 scheduled PK samples for each patient during and after infusion</description>
        <time_frame>Based on PK samples during and after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Total of AZD1305 (Umol*h/L)</title>
          <description>A total of 13 scheduled PK samples for each patient during and after infusion</description>
          <units>umol*h/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.97" lower_limit="0.97" upper_limit="2.21"/>
                    <measurement group_id="O2" value="4.97" spread="2.70" lower_limit="2.70" upper_limit="10.0"/>
                    <measurement group_id="O3" value="10.3" spread="5.71" lower_limit="5.71" upper_limit="18.9"/>
                    <measurement group_id="O4" value="17.3" spread="16.5" lower_limit="16.5" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Had at Least One AE</title>
        <description>Number of patients</description>
        <time_frame>During active treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1305 Dose Group 1</title>
            <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
          </group>
          <group group_id="O2">
            <title>AZD1305 Dose Group 2</title>
            <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
          </group>
          <group group_id="O3">
            <title>AZD1305 Dose Group 3</title>
            <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
          </group>
          <group group_id="O4">
            <title>AZD1305 Dose Group 4</title>
            <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Corresponding placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had at Least One AE</title>
          <description>Number of patients</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1305 Dose Group 1</title>
          <description>Loading dose 15 min at 43.5 mg/h, Maintenance dose maximum 60 additional min at 19.6 mg/h</description>
        </group>
        <group group_id="E2">
          <title>AZD1305 Dose Group 2</title>
          <description>Loading dose 15 min at 130.4 mg/h, Maintenance dose maximum 60 additional min at 58.7 mg/h</description>
        </group>
        <group group_id="E3">
          <title>AZD1305 Dose Group 3</title>
          <description>Loading dose 15 min at 325.9 mg/h, Maintenance dose maximum 60 additional min at 146.6 mg/h</description>
        </group>
        <group group_id="E4">
          <title>AZD1305 Dose Group 4</title>
          <description>Loading dose 15 min at 488.8 mg/h, Maintenance dose maximum 60 additional min at 220.0 mg/h</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Corresponding placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia And Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="1"/>
                <counts group_id="E4" subjects_affected="1"/>
                <counts group_id="E5" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

